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Abstract
Background: Chronic myeloid leukemia (CML) is driven by the fusion kinase Bcr-Abl. Bcr-Abl tyrosine kinase
inhibitors (TKIs), such as imatinib mesylate (IM), revolutionized CML therapy. Nevertheless, about 20 % of CMLs
display primary or acquired TKI resistance. TKI resistance can be either caused by mutations within the Bcr-Abl
kinase domain or by aberrant signaling by its effectors, e.g. Lyn or Gab2. Bcr-Abl mutations are frequently
observed in TKI resistance and can only in some cases be overcome by second line TKIs. In addition, we have
previously shown that the formation of Gab2 complexes can be regulated by Bcr-Abl and that Gab2 signaling
counteracts the efficacy of four distinct Bcr-Abl inhibitors. Therefore, TKI resistance still represents a challenge
for disease management and alternative therapies are urgently needed.
Findings: Using different CML cell lines and models, we identified the clinically approved TKIs sorafenib (SF) and
axitinib (AX) as drugs overcoming the resistance mediated by the Bcr AblT315I mutant as well as the one
mediated by Gab2 and LynY508F. In addition, we demonstrated that AX mainly affects the Bcr-Abl/Grb2/Gab2
axis, whereas SF seems to act independently of the fusion kinase and most likely by blocking signaling
pathways up- and downstream of Gab2.
Conclusion: We demonstrate that SF and AX show potency in various and mechanistically distinct scenarios of
TKI resistance, including Bcr-AblT315I as well as Lyn- and Gab2-mediated resistances. Our data invites for further
evaluation und consideration of these inhibitors in the treatment of TKI resistant CML.
Keywords: Chronic myeloid leukemia, CML, TKI resistance, Imatinib, Sorafenib, Axitinib, Ponatinib, Gab2,
Hyperactive Lyn, Bcr-Abl
Findings
Chronic myeloid leukemia (CML) represents about 20 %
of all cases of adult leukemia and is caused by a chromo-
somal translocation between chromosomes 9 and 22 lead-
ing to the expression of the fusion kinase Bcr-Abl [1].
This oncogenic tyrosine kinase generates its own signaling
network with various components such as the Src kinase
Lyn or the docking protein Gab2. Bcr-Abl tyrosine kinase
inhibitors (TKIs), such as Imatinib mesylate (IM), revolu-
tionized CML therapy. Nevertheless, about 20 % of CMLs
display primary or acquired TKI resistance, which repre-
sents a challenge for disease management [2]. TKI resist-
ance is often, but not exclusively, caused by mutations
within the kinase domain of Bcr-Abl [3] (Fig. 1a) and can
in some cases be overcome by second generation TKIs,
like dasatinib (DST), nilotinib (NL), or ponatinib (PO). In
the case of the gatekeeper mutation T315I, PO is the only
clinically approved inhibitor showing a therapeutic effect.
However, cardio-vascular side-effects often accompany
PO treatment [4] and therefore alternative therapies are
urgently needed. In addition, about 40 % of resistances are
Bcr-Abl mutation-independent [5] and still ill-defined at
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the molecular level. These resistances are often caused by
aberrant signaling of Bcr-Abl effectors such as the docking
protein Gab2 [6–8] or the Src kinase Lyn [9] (Fig. 1a).
Using different CML cell lines and models, we aimed to
identify new approaches to overcome TKI resistance
caused by Bcr-Abl mutations or aberrant downstream sig-
naling. Therefore, we screened inhibitors for their ability
to inhibit the activity of T315I mutated Bcr-Abl, or to
break Gab2- or Lyn-mediated resistance. Our previous
work on Gab2 mediated TKI resistance in CML cells sug-
gested that this docking protein, due to its position down-
stream of both growth factor receptors and Bcr-Abl [7],
protects against TKIs as it can be tyrosine phosphorylated
by the former and thereby drive the activation of pro-
leukemogenic pathways in the absence of Bcr-Abl activity.
Therefore, we chose inhibitors of growth factor receptors,
as they are known to play a role in primary TKI resistance
and to promote Gab2 and Lyn signaling [10, 11]. We iden-
tified the clinically approved multikinase inhibitors sorafe-
nib (SF) and axitinib (AX) as compounds reducing the
viability and metabolic activity of Bcr-Abl transformed
Ba/F3 cells (Additional file 1: Figure S1A/B). While SF
mainly targets Raf-1 and B-Raf, both compounds in-
hibit the VEGF receptors 1–3 [12, 13]. Interestingly,
these inhibitors were significantly less active in non-
transformed Ba/F3 cells, suggesting an inhibition spe-
cific for Bcr-Abl or its signaling network (Additional
file 1: Figure S1A/B). In contrast, the FLT3/PDGFR
inhibitors tandutinib (TD) and sunitinib (Sun) [14, 15]
displayed activity in Bcr-Abl transformed and non-
transformed Ba/F3 cells (Additional file 1: Figure S1A).
Next, we tested SF and AX in KBM-5 CML cells, either
expressing wildtype (wt) or mutant Bcr-Abl (T315I)
from its endogenous Philadelphia chromosome [16].
Based on previous publications showing titrations of SF
in IM resistant CML models [17, 18], we chose a con-
centration of 10 μM. For AX, we titrated the optimal
inhibitor concentration using an MTT assay (Add-
itional file 1: Figure S1C). Both inhibitors overcame
TKI resistance imposed by Bcr-AblT315I (Fig. 1b/c and
Additional file 1: Figure S1C). The efficacy of SF and
AX was comparable to PO, while the classical TKIs IM,
DST and NL only affected KBM5 cells lacking the
T315I mutation (Fig. 1b/c). Interestingly, AX showed a
higher efficacy in downregulating the phosphorylation
of ABL (Y245) and CRKL (Y207) in Bcr-Ablwt and Bcr-
AblT315I cells compared to SF indicating that AX has a
higher impact on the Bcr-Abl activity (Figs. 1d and
Additional file 2: Figure S2A). However, SF, AX and PO
reduced the phosphorylation of ERK and Gab2 (Y452)
in Bcr-Ablwt and Bcr-AblT315I expressing cells, whereas
IM, DST and NL were only active in the former. Thus,
SF and AX break T315I mediated resistance (Fig. 1d
and Additional file 2: Figure S2A). In addition, these re-
sults suggest that the phosphorylation of Gab2 (Y452)
might serve as a valuable biomarker in CML manage-
ment. Our data is in line with very recent manuscripts by
Pemovska et al. and Okabe et al. demonstrating the
potency of axitinib in Bcr-AblT315I positive Ba/F3 and
patient-derived cells [19, 20]. In contrast to the other in-
hibitors, SF provoked an upregulation of pAKT (Fig. 1d
and Additional file 2: Figure S2A), which might be ex-
plained by the strong inhibition of the ERK pathway by SF
and therefore the loss of a negative feedback on the PI3K/
AKT pathway [21]. However, SF effectively kills Bcr-Ablwt
and Bcr-AblT315I expressing cells (Fig. 1b/c), which is also
supported by an independent study showing effects of SF
on Bcr-Abl positive cells [17].
Bcr-Abl mutation independent TKI resistance repre-
sents an underestimated and mechanistically less-defined
problem in CML therapy and accounts for about 40 % of
TKI refractory disease, thereby representing a serious clin-
ical problem [5]. Therefore, we tested all clinically used
TKIs of our panel, i.e. IM, DST, NL and PO but also SF
and AX, in Lyn- and Gab2-mediated TKI resistance. First,
we analyzed K562 cells overexpressing the hyperactive
Lyn mutant Y508F, which displayed IM resistance in an
independent study [9]. Again, SF and AX reduced the via-
bility and metabolic activity in this setting (Additional file
1: Figure S1D/E). Interestingly, DST, NL and PO also
overcame LynY508F-mediated resistance (Additional file 1:
Figure S1D/E), suggesting that Lyn-mediated resilience
represents only a minor and less critical mechanism of
TKI resistance.
Recently, we demonstrated that Gab2, a critical effector
of Bcr-Abl in myeloid transformation [6], protects CML
cells from IM, DST and NL [7]. We also provided several
lines of evidence that this docking protein is increasingly
(See figure on previous page.)
Fig. 1 Sorafenib and axitinib can overcome TKI resistance. a Overview of resistance mechanisms in CML. b/c KBM5 and KBM5-T315I cells were exposed
to the indicated inhibitors or DMSO for 48 h. Cells were stained with 7-AAD and assessed for viability (b) or metabolic activity (MTT assay) (c). d KBM5
and KBM5-T315I cells were exposed to the indicated inhibitors or DMSO for 4 h. Cells were analyzed by western blotting using the indicated
antibodies. e/f K562tet Gab2 cells, exposed to 1 μg/ml doxycycline 48 h prior to the treatment or non-induced cells were treated with the
indicated inhibitors or DMSO for 72 h. Cells were stained with PI and assessed for viability (e) or metabolic activity (MTT-assay) (f). g K562tet
Vector and Gab2 cells were exposed to 1 μg/ml doxycycline 48 h prior to the treatment with the indicated inhibitors or DMSO for 4 h. Cells
were analyzed by western blotting using the indicated antibodies. Relevant statistically significant effects are indicated by asterisks, all statistical data
can be found in the supplement (b/c/e/f; Additional file 8 )
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expressed in myeloid cells from patients with TKI-
refractory disease [7] or blast crisis [22], a stage known for
its insensitivity to Bcr-Abl inhibitors. Therefore, we tested
SF and AX in K562 cells with conditional Gab2 overex-
pression [7, 8]. As observed previously [7], overexpression
of Gab2 conferred resistance towards IM, DST and NL
(Fig. 1e/f). Interestingly, even PO failed to overcome Gab2
mediated resistance, further underscoring the critical role
of Gab2 as a mediator of TKI resistance. Instead, SF and
AX bypassed the protective effect of Gab2 (Fig. 1e/f). Like
in KBM-5 cells, SF had a less pronounced effect on Bcr-
Abl auto-phosphorylation, while AX reduced Bcr-ABL
phosphorylation (Y245) (Fig. 1g and Additional file 2: Fig-
ure S2B). Interestingly, Gab2 overexpression induced an
upregulation of AKT and ERK phosphorylation but not
any changes in Bcr-Abl auto-phosphorylation, suggesting
that Gab2 mediated resistance is caused by the activation
or maintenance of the PI3K and MAPK pathways rather
than by increasing Bcr-Abl activity (Fig. 1g).
To further investigate the influence of SF and AX on
the Bcr-Abl/Gab2 signaling axis, we performed SILAC-
based quantitative mass spectrometry (MS) as de-
scribed previously [8]. Following labelling, HA-tagged
Gab2 complexes were purified from IM, SF and AX
treated K562 cells (Fig. 2a). This revealed that IM and
AX remove an overlapping spectrum of Gab2 interactors
(Fig. 2b/c and Additional file 3: Figure S3; Additional files
4, 5 and 6: Tables S1/S2/S3). These interactors were
mostly known Gab2 partners, like PI3K components,
SHP2, SHIP2, SHC, Grb2 or PLCγ but also novel inter-
action partners like MAP4K5 and Aurora A. These results
are in line with the changes in Gab2 complex composition
of IM or DS treated K562 cells [8, 23], Interestingly, SF
hardly affected Gab2 interactions, but influenced proteins
previously not linked to Gab2 such as MEGF8 or
SUSD1. It remains to be tested whether the interaction
of Gab2 to MEGF8 or SUSD1 plays a role in CML.
MEGF8 and SUSD1 are single pass transmembrane
proteins. MEGF8 is known to play a role in develop-
ment and germline mutations of MEGF8 have been re-
cently linked to Carpenter syndrome subtype 2 associated
with defective lateralization [24, 25], whereas SUSD1 with
its two Sushi domains represents an almost uncharac-
terized protein. These interactions invite for further
functional studies. However, the contrasting recruit-
ment patterns of the Gab2 interaction partners illus-
trate the different mode of action of SF and the other
TKIs used in this (Fig. 2c) and previous experiments
[8].
We also analyzed the phosphorylation of Gab2 (Fig. 2d;
Additional file 7: Table S4). In full agreement with the in-
teractome data, Gab2 phosphorylation sites were mark-
edly reduced upon IM and AX but not by SF treatment.
In addition, an independent Gab2 IP was performed to
confirm our MS results and to test the other inhibitors
DST, NL and PO (Fig. 2e). As in the MS experiments, SF
hardly influenced protein-protein interactions of Gab2,
while AX downregulated the its interaction with the PI3K
subunit p85, SHP2 and SHC. DST and NL had similar ef-
fects as IM. The effects of PO were in most cases more
pronounced as for IM, DST and NL, suggesting a stronger
inhibition of Bcr-Abl activity. Thus, like IM, DST, NL and
PO, AX acts mainly on the Bcr-Abl-Grb2-Gab2 axis,
whereas SF seems to act independently and most likely by
affecting signaling pathways up- and downstream of Gab2.
However, as AX is able to break Gab2 mediated resistance,
this compound might additionally inhibit other kinases
phosphorylating the docking sites on Gab2 and might
therefore also cause similar effects as sorafenib (Fig. 2f).
Thus, the efficacy of AX in Bcr-AblT315I mutant CML
might be explained by its on-target action as a selective in-
hibitor for this gatekeeper mutant [19] and by “off-target”
effects eliminating back-up pathways leading to Gab2
tyrosine phosphorylation and downstream signaling.
In summary, we demonstrate that SF and AX show
potency in various and mechanistically distinct scenar-
ios of TKI resistance, including Bcr-AblT315I as well as
Lyn-mediated resistance. In the light of the clinically
observed side effects of the currently in TKI resistant
CML used inhibitor PO, SF and AX might serve as
valuable alternatives. In addition, we could show that SF
and AX are able to bypass the protective effect of Gab2,
while PO failed to do so (Fig. 2g) as we had reported pre-
viously for other ATP competitive and allosteric inhibitors
(See figure on previous page.)
Fig. 2 The interactome and phosphorylation status of Gab2 is differentially affected by sorafenib and axitinib. a Differentially SILAC labeled
K562tet/Gab2-HA cells were exposed to 1 μg/ml doxycycline (to induce Gab2-HA expression) prior to treatment with either 1 μM imatinib,
10 μM sorafenib or 1 μM axitinib, and DMSO as control, respectively for 4 h. Purified Gab2 protein complexes were combined 1:1:1 and analyzed by
LC-MS/MS. A biological replicate with reversed labels was performed and results of replicates correlated well. Protein interactions dependent on
inhibitor sensitive phosphorylation sites will be reduced. b Venn diagram of imatinib, sorafenib and axitinib treatment showing TKI-sensitive
Gab2 interactors. c/d TKI-sensitive changes in the Gab2 interactome (c) and the phosphorylation of Gab2 (d). Each bar represents an independent
experiment (e) K562tet Vector and Gab2 cells were exposed to 1 μg/ml doxycycline prior to the treatment with the indicated inhibitors. Purified Gab2
complexes were analyzed using the indicated antibodies. f Schematic model of TKI action on the Bcr-Abl/Grb2/Gab2 signaling complex. Axitinib acts
like imatinib, dasatinb, nilotinib and ponatinib mainly through the Bcr-Abl/Grb2/Gab2 axis, whereas sorafenib seems to act independently and most
likely by affecting signaling pathways up- and downstream of Gab2. Due to the effects of axitinib on Gab2 mediated resistance, axitinib might act
additionally also on other kinases, similar to sorafenib. g Diagram showing the potency of sorafenib and axitinib in all tested TKI resistances
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specifically designed to block Bcr-Abl activity. Our data
invites for further evaluation und consideration of SF and
AX in the treatment of TKI resistant CML.
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file 8: Supplementary Methods and Supplementary Statis-
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Additional file 1: Figure S1. (A/B) Ba/F3 vector cells and cells
transformed with pBABE Bcr-Abl were exposed to the indicated inhibitors
or DMSO for 48 h. Cells were stained with 7-AAD and assessed for viability
(A) or metabolic activity (MTT assay) (B). (C) KBM5 and KBM5-T315I cells were
exposed to the indicated inhibitors or DMSO for 48 h. Cells were assessed
for metabolic activity (MTT assay) (D/E) K562 cells overexpressing Lyn or
hyperactive Lyn Y508F were exposed to the indicated inhibitors or DMSO
for 48 h. Cells were stained with 7-AAD and assessed for viability (D) or
metabolic activity (MTT assay) (E). Relevant statistically significant effects are
indicated by asterisks, all statistical data can be found above. (PDF 176 kb)
Additional file 2: Figure S2. (A/B) Western Blot quantification of
Fig. 1d and 1G, n = 3, using FusionCapt 7.06 (Vilber Lourmat, Germany).
(PDF 184 kb)
Additional file 3: Figure S3. Correlation of biological replicates. GAB2
protein complexes were enriched by IP. Contaminating proteins were
removed and ratios normalized to GAB2. Proteins changing significantly
interactions with GAB2 by indicated inhibitor treatments are highlighted
red. Signigicant affeceted proteins are determined using Significance A
(MaxQuant, p < 0.05, BH corrected). Proteins are highlighted if minimally
one IP exhibited a signifcant regulation and the other IP showed the
same trend (see Additional files 4, 5 and 6: Tables S1/S2/S3). (PDF 203 kb)
Additional file 4: Table S1. Anti-GAB2 IP of Imatinib vs DMSO treated
cells. Experiment 1 and 2 are averages of two replicates each. SILAC
ratios are normalized to GAB2 and log2 transformed. Significant affected
proteins are determined using Significance A (MaxQuant, p < 0.05, BH
corrected). Proteins are shortlisted if minimally one IP exhibited a significant
regulation and the other IP showed the same trend (see Additional file 2:
Figure S2). PEP: posterior error probability. (XLSX 231 kb)
Additional file 5: Table S2. Anti-GAB2 IP of Sorafenib vs DMSO treated
cells. SILAC ratios are normalized to GAB2 and log2 transformed. Significant
affected proteins are determined using Significance A (MaxQuant, p < 0.05,
BH corrected). Proteins are shortlisted if minimally one IP exhibited a
significant regulation and the other IP showed the same trend (see
Additional file 2: Figure S2). PEP: posterior error probability. (XLSX 174 kb)
Additional file 6: Table S3. Anti-GAB2 IP of Axitinib vs DMSO treated
cells. SILAC ratios are normalized to GAB2 and log2 transformed. Significant
affected proteins are determined using Significance A (MaxQuant, p < 0.05,
BH corrected). Proteins are shortlisted if minimally one IP exhibited a
significant regulation and the other IP showed the same trend (see
Additional file 2: Figure S2). PEP: posterior error probability. (XLSX 185 kb)
Additional file 7: Table S4. Anti-GAB2 IP of Imatinib, Axitinib and
Sorafenib vs DMSO treated cells. SILAC ratios are normalized to GAB2.
Only sites with localization probabilities greater 0.75 and Andromeda
scores greater 40 are shown. PEP: posterior error probability. (XLSX 12 kb)
Additional file 8: Supplementary Methods and Supplementary
Statistics. (PDF 297 kb)
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